MISSION STATEMENT

At Co-Diagnostics, we are passionate about providing the most robust and innovative molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications, especially to those regions where pricing is paramount. Our proprietary molecular diagnostics technology is paving the way for innovation in disease detection and life sciences research through our enhanced detection of genetic material. Because we own our platform, we are able to accomplish this faster and more economically, allowing for wider margins while still positioning Co-Diagnostics to be the worldwide low-cost leader of molecular diagnostics services.

About Co-Diagnostics

Co-Diagnostics, Inc. is a molecular diagnostics company with unique, patented Polymerase Chain Reaction (“PCR”) testing technology. A Utah corporation headquartered in Salt Lake City, Utah, we commercialize our innovative patented and patent-pending technology through sales, development and licensing, to quickly develop molecular diagnostics that are more cost-efficient and perform better than traditional technologies of the past.

Our technology has broad molecular applications: multiplexing, single nucleotide polymorphism (SNP) and mutation detection, real-time or traditional PCR detection, genotyping, RNA expression, and Sanger or next generation sequencing. The range of applications opens doors for us to develop tests related to multiple disciplines: infectious disease, oncology, transfusion medicine, pharmacogenetics, therapeutics, liquid biopsy, agriculture, or veterinary medicine. Researchers are able to quantify and analyze rare alleles and mutations using our advanced platform that includes unique, accelerated, ultra-specific attributes. Leading companies are applying our technology in a wide range of disciplines that can increase the speed, lower the cost and enhance the accuracy of their next generation sequencing. Other major advances associated with our platform include shorter turnaround times and higher productivity that boost automated workflow, thereby ensuring efficient detection and amplification of genetic materials with accurate results.

The technology represents a significant technical advance in the design of qPCR platforms, enabling us to efficiently detect pathogenic microbes such as mycobacterium tuberculosis at a fraction of the cost of competitors. In addition, the unique capabilities in real multiplexing and SNP detection make it possible to identify multiple disease or cancer targets in a single test. Our menu is rapidly growing and aims to serve a worldwide market with superior affordable tests.

Co-Diagnostics, Inc is ISO 13485:2016 (Medical Devices) certified for the design and manufacture of medical device products for the handling, stabilization, separation, purification, amplification, and detection of nucleic acids. Click HERE to request a copy of our ISO 13485:2016 certificate.